MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
Atlanta, Georgia 30329
June 26-27, 2019

AGENDA ITEM

Wednesday, June 26
8:00 Welcome & Introductions
Dr. Jose Romero (ACIP Chair)
Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

8:30 Pneumococcal Vaccines
Introduction
Dr. Grace Lee (ACIP, WG Chair)
Summary of the Evidence to Recommendations (EtR) Framework
Dr. Almea Matanock (CDC/NCIRD)

10:00 Break

10:15 Human Papillomavirus Vaccines
Introduction
Dr. Peter Szilagyi (ACIP, WG Chair)
9vHPV Immunogenicity Trial in Mid-Adult Females
TBD
Overview of Health Economic Models for HPV Vaccination of Mid-Adults
Dr. Harrell Chesson (CDC/NCHHSTP)
Evidence to Recommendations (EtR) Framework
Dr. Elissa Meites (CDC/NCIRD)
Work Group Considerations and Proposed Policy Options
Dr. Lauri Markowitz (CDC/NCIRD)

11:45 Lunch

1:00 Combination Vaccines
Introduction
Dr. Kelly Moore (ACIP, WG Chair)
Summary and Relevant Evidence to Recommendation Information
Dr. Sara Oliver (CDC/NCIRD)

1:30 Public Comment

2:30 Break

2:45 VOTES
Pneumococcal Vaccines
Dr. Almea Matanock (CDC/NCIRD)
Human Papillomavirus
Dr. Lauri Markowitz (CDC/NCIRD)

VFC VOTES
Diphtheria, Tetanus, & Pertussis
Dr. Jeanne Santoli (CDC/NCIRD)
Haemophilus influenzae type b
Hepatitis B
Polio

3:45 Break

4:00 Zoster Vaccines
Introduction
Dr. Kelly Moore (ACIP, WG Chair)
Update: Safety Monitoring and Surveillance for Recombinant Zoster Vaccine (RZV)
Dr. Tom Shimabukuro (CDC/NCEZID)
Herpes Zoster Work Group Summary
Dr. Kathleen Dooling (CDC/NCIRD)

4:25 Pertussis Vaccines
Introduction
Dr. Henry Bernstein (ACIP, WG Chair)
EtR Framework, Work Group Considerations and Proposed Policy Options
Dr. Fiona Havers (CDC/NCIRD)

4:55 Rabies Vaccine
Dr. Sharon Frey (ACIP, WG Chair)

5:05 Adjourn
Thursday, June 27

8:00 Unfinished Business and Agency Updates
   CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

8:30 Influenza Vaccines
   Introduction
   2018-19 U.S. Influenza Activity
   2018-19 Influenza Vaccine Effectiveness
   2018-19 Influenza Vaccine Safety
   Proposed Recommendations for 2019-20

9:45 Break

10:00 Hepatitis A Vaccines
   Introduction
   Proposed Recommendations for Use of Hepatitis A

11:15 Break

11:30 Meningococcal Vaccines
   Introduction

12:30 Lunch

1:30 Public Comment

1:45 VOTES & VFC VOTES
   Influenza Vaccines
   Influenza VFC
   Hepatitis A Vaccines
   Hepatitis A
   Meningococca
   Meningococcal VFC

2:30 Break

2:45 Dengue Vaccine
   Introduction
   Dengue Epidemiology in the U.S.
   Dengvaxia Phase III Clinical Trials and Long Term Follow Up
   Work Group Considerations and Next Steps

3:45 Vaccine Supply Update

3:50 Adjourn

Acronyms
AI/AN American Indian/Alaska Native
AVA Anthrax vaccine absorbed
CDC Centers for Disease Control & Prevention
CMS Centers for Medicare and Medicaid Services
DoD Department of Defense
DVA Department of Veterans Affairs
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
Hib Haemophilus influenzae type b
HRSA Health Resources and Services Administration
IHS Indian Health Service
MenB Serogroup B meningococcal vaccine
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NVPO National Vaccine Program Office
PCV13 13-valent pneumococcal conjugate vaccine
RZV Recombinant zoster vaccine
WG Work Group
VE Vaccine effectiveness